BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors.

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

How quickly one group gains the upper hand determines ... For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and pain related to ...

Health secretary Wes Streeting has rejected proposals by the House of Lords that the government should exclude food industry bosses from helping to plan the battle against obesity. Speaking to the BBC ...

Soumya Swaminathan, ex-WHO Chief Scientist, states that unhealthy diets and sedentary lifestyles are behind India’s growing abdominal obesity rates. Soumya Swaminathan, former WHO Chief ...

MSK thoracic medical oncologist Justin Jee, MD, PhD, (left) and computational oncologist Ed Reznik, PhD, led a team of researchers who found that obesity is linked to driver mutations in tumors that ...

Although effective for obesity treatment, these medications raise concerns over the potential for significant muscle loss (1 Trusted Source Muscle matters: the effects of medically induced ...

2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity ...

Robust debuts by drug developers Bicara Therapeutics , MBX Biosciences, BioAge Labs and Upstream Bio are also encouraging ... metabolic diseases and obesity, providing several paths to potential ...

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...